Fostamatinib (R788)

Fostamatinib (R788)は一種の活性代謝物R406の前駆薬で、一種のSyk阻害剤で、無細胞試験で、このIC50値が41 nMです。Fostamatinib (R788)はSykを有効に抑制しますが、Lynを抑制しなくて、Sykに作用する効果はFlt3に作用する効果より5倍が高くなります。臨床3期。

価格 在庫  
USD 340 あり
USD 592 あり
USD 819 あり
USD 1096 あり
電話番号: + 81 3-5632-9610mail@cosmobio.co.jp

Fostamatinib (R788) 化学構造
分子量: 580.46

高品質保証

カスタマーフィードバック(1)

MSDS

製品説明

  • Compare Syk Inhibitors
    Syk製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Fostamatinib (R788)は一種の活性代謝物R406の前駆薬で、一種のSyk阻害剤で、無細胞試験で、このIC50値が41 nMです。Fostamatinib (R788)はSykを有効に抑制しますが、Lynを抑制しなくて、Sykに作用する効果はFlt3に作用する効果より5倍が高くなります。臨床3期。
ターゲット

Syk

Adenosine A3 receptor

Adenosine transporter

Monoamine transporter

IC50

41 nM

81 nM

1.84 μM

2.74 μM [1]

In vitro試験 R788 is a prodrug of the spleen tyrosine kinase (Syk) inhibitor R406. R788 is a competitive inhibitor for ATP binding with a Ki of 30 nM. R788 dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM. R788 also inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNFα, IL-8, and GM-CSF. Inhibition of Syk by R788 results in inhibition of all phosphorylation events downstream of Syk signaling. Next to FcϵRI signaling in CHMC, R788 most potently inhibits the signaling of IL-4 and IL-2 receptors. R788 specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes. [1] R788 induces apoptosis of the majority of examined DLBCL cell lines. In R788-sensitive DLBCL cell lines, R788 specifically inhibits both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). [2]
In vivo試験 Oral administration of R788 to mice reduces immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models. [1] In another study, R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolongs survival of the treated animals. [3] R788 demonstrates a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of rheumatoid arthritis. [4]
臨床試験 R788 has entered in a phase III clinical trial in the treatment of rheumatoid arthritis.
特集 Converted into its active metabolite R406 in vivo.

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Fluorescence polarization kinase assay and Ki determination The fluorescence polarization reactions are performed. For Ki determination, duplicate 200-μL reactions are set up at eight different ATP concentrations from 200 μM (2-fold serial dilutions) in the presence of either DMSO or R788 at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 μL of each reaction is removed and quenched to stop the reaction. For each concentration of R788, the rate of reaction at each concentration of ATP is determined and plotted against the ATP concentration to determine the apparent Km and Vmax (maximal rate). Finally the apparent Km (or apparent Ki/Vmax) is plotted against the inhibitor concentration to determine the Ki.

細胞アッセイ:

[1]

細胞株 Cultured human mast cells (CHMC)
濃度 0 μM -100 μM
反応時間 30 minutes
実験の流れ

Cultured human mast cells (CHMC) are derived from cord blood CD34+ progenitor cells and grown, primed, and stimulated and shown in supplemental data. Before stimulation, cells are incubated with R788 or DMSO for 30 minutes. Cells are then stimulated with either 0.25 to 2 mg/mL anti-IgE or anti-IgG or 2 μM ionomycin. For tryptase measurement, ∼1500 cells per well are stimulated for 30 min in modified Tyrode's buffer. For LTC4 and cytokine production, 100,000 cells per well are stimulated for 1 or 7 hours, respectively. Tryptase activity is measured by luminescence readout of a peptide substrate, and LTC4 and cytokines are measured using Luminex multiplex technology.

動物実験:

[1]

動物モデル Balb/c mice with arthritis
製剤 35% TPGS, 60% PEG 400, 5% propylene glycol
投薬量 1 mg/kg or 5 mg/kg
投与方法 Orally b.i.d

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Fostamatinib (R788) SDF
分子量 580.46
化学式

C23H26FN6O9P

CAS No. 901119-35-5
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 116 mg/mL (199.84 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate

文献中の引用 (2)

Frequently Asked Questions

  • Question 1
    What’s the difference between S2625 and S2206?

    Answer: S2206 is more stable than S2625. The water solubility of S2206 is better than S2625. The absorption of S2206 is harder than S2625, so you need to test the suitable dosage if you use the product in animal assays. The potency of S2206 and S2625 is similar.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Syk 阻害剤

  • PX-478 2HCl

    PX-478 2HClは一種の経口活性をしている、選択性的なHIF-1α阻害剤です。臨床1期。

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878)は一種の選択性的で、経口有効なFAK阻害剤です。臨床2期。

  • SU6656

    SU6656は一種の選択性的なSrc家族キナーゼ阻害剤で、Src、Yes、LynとFynに作用する時の IC50値が280 nM、20 nM、130 nMと170 nMにそれぞれ分かれることです。

  • Dasatinib Monohydrate

    Dasatinib Monohydrateは一種の新たで、有効な多ターゲット阻害剤で、Abl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。

  • R406 (free base)

    R406 (free base)は一種の有効なSyk阻害剤で、無細胞試験でIC50値が41 nMです。R406 (free base)はSykを有効に抑制しますが、Lynを抑制しなくて、Sykに作用する効果はFlt3に作用する効果より5倍が高くなります。臨床1期。

  • R406

    R406は一種の有効なSyk阻害剤で、無細胞実験でIC50値が41 nMです。R406はSykを抑制する作用が強くても、Lynを抑制しません。R406は、Sykに作用する効果はFlt3に作用する効果より5倍が高くなります。臨床1期。

    Features:Lead drug candidate for rheumatoid arthritis.

  • R788 (Fostamatinib) Disodium

    R788 (Fostamatinib) disodiumは一種の活性代謝物R406の前駆薬で、一種のSyk阻害剤で、無細胞試験で、このIC50値が41 nMです。R788 (Fostamatinib) disodiumはSykを有効に抑制しますが、Lynを抑制しなくて、Sykに作用する効果はFlt3に作用する効果より5倍が高くなります。臨床3期。

    Features:Clinically used oral formulation of R406.

  • Piceatannol

    Piceatannolは一種の天然スチルベン(stilbene)で、一種の選択性的なSyk阻害剤ですが、Sykに作用する選択性はLynに作用する選択性より10倍左右が高くなります。

  • PRT062607 (P505-15, BIIB057) HCl

    PRT062607 (P505-15, BIIB057) HCl は一種の新たで、高度選択性的なSyk阻害剤で、無細胞試験でIC50値が1 nMですが、Sykに作用する選択性は、Fgr、Lyn、FAK、Pyk2とZap70に作用する選択性より80倍以上がそれぞれ高くなります。

最近チェックしたアイテム

Tags: Fostamatinib (R788)を買う | Fostamatinib (R788)供給者 | Fostamatinib (R788)を購入する | Fostamatinib (R788)費用 | Fostamatinib (R788)生産者 | オーダーFostamatinib (R788) | Fostamatinib (R788)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ